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What's already known about this topic?
Less frequent follow-up than is currently recommended for patients with AJCC stage I or II melanoma has been proposed and a trial is underway in the Netherlands.
What does this study add?
To revise guidelines and successfully implement recommended changes it is important to adequately understand the rationale underpinning existing clinical practice. This study from two Australian specialised centres describes melanoma clinicians' perspectives on the functions of follow-up of patients with early stage melanoma, the psychosocial factors that influence follow-up schedules, and some important considerations for extending intervals.
ABSTRACT Background
There is limited evidence on the relative effectiveness of different follow-up schedules for patients with AJCC stage I or II melanoma but less frequent follow-up than is currently recommended has been proposed. To revise guidelines and successfully implement future changes it is important to understand the rationale underpinning existing clinical practice.
Objectives
To describe melanoma clinicians' perspectives on the functions of follow-up, factors that influence follow-up intervals, and important considerations for extending intervals.
Method
In-depth qualitative study that comprised semi-structured interviews with 16 clinicians (surgical oncologists, dermatologists, melanoma unit GPs) who conduct post-treatment follow-up at two of Australia's largest specialist centres.
Results
Follow-up in specialist centres is conducted to detect early any recurrences or new primary melanomas, manage patient anxiety, support patient-self care, and as a part of shared care.
Follow-up is also an opportunity to review practice and provide data for research.
Recommended intervals are based on guidelines, but account for each patient's clinical risk profile, level of anxiety, and the visits required to establish rapport and provide patient education. Longer-term considerations are patient preferences and capacity to engage in skin self-examination, and how clinicians manage suspicious lesions to minimise the possibility of missing a new melanoma.
Conclusions
If evidence supports extended follow-up intervals for early stage melanoma, less frequent visits are more likely to be adopted after the first year when patients are less anxious and sufficiently prepared to conduct self-examination. Clinicians may also retain existing schedules for highly anxious patients or those unable to examine themselves.
INTRODUCTION
There is significant variation between countries in the post-treatment follow-up of patients with AJCC (American Joint Committee on Cancer) stage I/II melanoma 1 , with recommended schedules based on patients' yearly risk of melanoma recurrence, patterns of recurrence, patient adherence with schedules, consensus opinion among melanoma experts and historical precedent. 2, 3 There are no completed randomised trials of alternative follow-up schedules, although one is currently under way in the Netherlands. 4 However, most schedules agree on two principles -more frequent follow-up for higher AJCC stages of melanoma, and reductions in the frequency of visits over time. 2 Current UK guidelines recommend that patients with stage IA melanoma have 2 to 4 follow-up visits in the first year only, while follow-up for patients with stage IB-IIC is 3-monthly for 3 years, and 6-monthly from 3 to 5 years. 5 Australian guidelines recommend longer (lifelong) follow-up for all patients with melanoma i.e. 6-monthly (stage I) or 3 to 4-monthly (stage II) for 5 years, and annually thereafter. 6 As the worldwide prevalence of melanoma continues to increase, post-treatment follow-up poses a significant burden on surgical oncologists, dermatologists and other clinicians. 3, [7] [8] [9] The majority of melanoma recurrences (62%) and most subsequent melanomas (73%) are detected by patients or their partners. 2, 10 It has been proposed that less frequent follow-up for patients with early stage disease could be safe and cost-effective. 10, 11 This is further supported by recent modelling in which reduced frequency of follow-up substantially reduced the number of lifetime visits required, with only a small number of patient diagnoses delayed by more than two months. 12 Extended follow-up intervals may also be appreciated by patients. A recent systematic review identified that while patients value the reassurance of regular skin examinations, many also experience anxiety associated with impending follow-up visits. Adherence to schedules can be highly variable, with up to half of patients dropping out of recommended follow-up programs in the first five years. Patients also report difficulties with attending hospital-based appointments due to the time and cost of travel, transport and parking difficulties, and long clinic waiting times. 13 When recommending changes to medical protocols it is important to examine both clinical and psychosocial effects, i.e. emotional, cognitive, social and behavioural outcomes. 14, 15 Psychosocial considerations impact on both patient wellbeing and clinical practice; for example, melanoma patients attending follow-up report unmet needs for emotional support, and melanoma clinicians may order additional tests (e.g. blood tests or imaging) to reassure patients. 13 To-date melanoma research has described patients' and general practitioners' The interviews, each lasting 30-60 minutes, were conducted face-to-face (n=12) or by telephone (n=4) and all were recorded and transcribed. Clinicians were asked to discuss the psychosocial aspects of follow-up and their views on follow-up intervals. Analysis was conducted as a group process in which 3 researchers (LR, KM and RM) read all transcripts and independently prepared analytical notes 16, 17 on the psychosocial functions of follow-up, and the key relationships between these aspects of care and follow-up schedules. This analysis was discussed in regular meetings where coding of the data was revised and refined, and explanations of observed relationships between categories were explored. Two participating clinicians were invited to provide feedback on the validity of the findings. 
RESULTS

The purpose of follow-up
Clinicians emphasised that the main goal of post-treatment melanoma follow-up was early detection of disease recurrence and/or new primary melanomas, and that routine skin checks should be conducted by an experienced clinician and by the patients themselves -ideally assisted by a family member to examine less accessible parts of the body. The purpose of patients attending follow-up at the specialist centres was reported to comprise a number of core functions (Table 1) :
(i) Direct clinical care: Clinical examination and skin checks, and providing reassurance and managing patient anxiety. Clinicians developed a comprehensive knowledge of individual patients' health, skin, particular lesions and psychosocial needs. They described two periods of peak anxiety among their patients: (a) in the first stages of follow-up when patients haven't yet had an opportunity to obtain or absorb all the relevant information, and need to spend time with a melanoma specialist to address their concerns; and (b) when they or their clinician identify a potential -and subsequently confirmed -recurrence or new melanoma. 
Factors that influence frequency of follow-up (intervals)
Routine follow-up was based on Australian guidelines 6 
Patients' needs and preferences
Clinicians described significant variation in how patients presented at follow-up. Many appeared anxious until clinical examination indicated there was no recurrence or new primary melanoma. The majority of patients readily accepted their clinician's recommendation on the required frequency of follow-up. A few, however, would request more frequent follow-up than would usually be advised on clinical indications alone. Clinicians also noted that some patients were reluctant to decrease their frequency of follow-up once a schedule had been established, e.g. patients who asked to retain existing schedules at the end of a clinical trial or after recurrence-free periods of 5 years or more. Some patients wanted more frequent reassurance because a family member or friend had died as a result of melanoma. Melanoma prevention television advertisements 18 , while valuable for increasing public awareness, also added to the anxiety of existing patients by graphically illustrating an undetected spread of melanoma. Where possible, clinicians tried to reassure and/or accommodate patients who felt anxious about extending follow-up intervals. Clinicians also noted that patient demand for frequent follow-up may be influenced by skin-cancer clinics in their neighbourhood offering routine 3-monthly monitoring for anyone with a history of melanoma.
Other patients were reported to be pleased when advised that they could reduce the frequency of clinical surveillance, both because they associated this with lessened risk, and because of the time and cost burden of attending for follow-up. Clinicians widely agreed that if there was good evidence for extending intervals in long-term follow-up with no adverse effects on patient outcomes (e.g. extending intervals from 3 to 6 months, or 6 to 12 months) they would be willing to make the changes, and that many of their patients would feel relieved to attend less often. It was also noted that less intensive monitoring may improve adherence to recommended follow-up, and that extended intervals may encourage patients to return more quickly if they found a suspicious lesion rather than waiting for their next scheduled appointment.
Establishing rapport and trust, and providing education to support patient self-care
All clinicians emphasised the importance of gaining the trust of patients and establishing good doctor-patient rapport as essential ingredients for effective patient education and a prerequisite for supporting patient self-care. Clinicians described the regular visits in the first 1-2 years post-diagnosis as important for getting to know their patients. Patients also needed multiple visits to absorb new information, to consider and discuss the implications of what they had learnt, and to ask questions and discuss concerns. Thus when considerations of a reduction in the frequency of follow-up were discussed, it was usually with the proviso of retaining 2-4 visits within the first year to support patient self-care. Clinicians also reported that good doctor-patient rapport helped patients to feel more able to make unscheduled return visits -particularly if they were concerned that the clinician may have missed something at the last appointment.
Patients' capacity for self-examination
A patient's apparent willingness and capacity to engage in skin self-examination was also identified as an important consideration in determining how often that patient was advised to return for clinical follow-up. More frequent schedules were adopted for those less able to examine themselves because they were older, had poor eyesight, no partner to assist with self-examination, or seemed otherwise unable or unwilling to conduct self-surveillance. The clinician's assessment of a patient's level of engagement and self-responsibility also influenced their approach in dealing with suspicious lesions. For example, if it was perceived that a patient was unlikely to notice changes in skin lesions, or if they had a history of nonadherence to recommended schedules, clinicians were more inclined to remove a suspicious lesion at that visit than to ask the patient to monitor it themselves and return for reassessment a few months later.
Preferred practice
Several clinicians noted the absence of trial evidence on the relative effectiveness of alternative follow-up schedules; thus recommended follow-up was thus based on differential rates of disease risk in melanoma patient populations, and also influenced by historical practice. To consider extending intervals beyond current guidelines, clinicians primarily wanted to know the likely effects on disease detection rates, and on the stage of disease at detection. Many clinicians noted that some melanomas can be very difficult to identify and that there was always a chance that a difficult lesion could be missed during clinical examination. Several clinicians reported that this caused them some concern and anxiety, and 
DISCUSSION
This study drew on the strengths of qualitative research 17 to provide an in-depth examination of melanoma unit clinicians' rationale for routine follow-up of patients with early stage melanoma. It documented the clinicians' perspectives on the functions of post-treatment follow-up, and described how they determined and adapted follow-up schedules. The participants in this study were from tertiary referral melanoma treatment and diagnostic units, and it is important to acknowledge that their perspectives as described in this paper may therefore differ to those of other clinicians conducting melanoma follow-up in other units, or in community-based practice. We believe, however, that the implications of the findings for any considerations of extended follow-up intervals may be readily generalised to other settings.
Implications for extending intervals in melanoma follow-up
Several potential benefits of extending existing intervals in the follow-up of AJCC stage I/II melanoma have been proposed. 4, [10] [11] [12] Clinicians in this study also reported that many of their patients would feel relieved if less frequent follow-up was recommended by their melanoma specialist -a view supported by patients themselves. 19 The It is important to retain provisions for several visits with an experienced melanoma clinician in the first year of follow-up in order to provide patients with relevant information, to meet their psychosocial needs, and enable development of good doctor-patient trust and rapport to support longer-term patient self-care. It is also essential to retain capacity for high quality patient education -particularly in first few follow-up visits -which should be conducted either by melanoma specialists or other clinicians with melanoma follow-up expertise.
Patients need to feel able to return to their melanoma specialist within 1-2 weeks if they, or another clinical provider, identify a suspicious lesion that could be a recurrence or new primary disease. Revised protocols should also retain flexibility for those patients who require more frequent follow-up than indicated by their melanoma risk profile alone. Finally, the rationale for any changes to established follow-up schedules must be clearly understood by the patients affected. This will rely on adequate opportunity to discuss revised schedules with a melanoma clinician to allay patients' anxiety, and to  Retain capacity for high quality patient education in early stages of follow-up.
 Ensure patients are able to return to a melanoma specialist at relatively short notice.
 Allow flexibility for those patients who require more frequent follow-up than indicated by melanoma risk profile alone.
 Ensure the rationale for changes to established schedules are understood and accepted by the patients affected.
